Axis-Shield's new commercialisation phase gets off to a "good start" in 2007
This article was originally published in Clinica
Anglo-Nordic IVD developer Axis-Shield said it succeeded in achieving "strong underlying growth" for 2007 in the face of a weak dollar and the continued decline in homocysteine revenues.
You may also be interested in...
Vydaqel saw its uptake take off in the US last year. UK’s NICE to pass judgement on cost effectiveness by June.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect.